Spero Therapeutics Inc
SPRO
Get informed when a big investor buys or sells
+ FollowMarket Cap$65.43M
Close$
$5.29
320.2% upside
Current Fair Value
320.2% upsideUndervalued by 320.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $65.43 Million |
|---|---|
| Enterprise Value | $16.86 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.15 |
| Beta | 1.48 |
| Outstanding Shares | 57,968,608 |
Return
| Return on Equity | 16.70% |
|---|---|
| Return on Assets | 13.99% |
| Return on Invested Capital | 10.74% |
Valuation & Multiples
| P/E Ratio | 8.07 |
|---|---|
| PEG | 1.75 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 0.37 |
| Enterprise Value to EBIT | 3.54 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.13 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 2.0888▲ 39.11% |
|---|---|
| Total Calls | 60,800▼ 5.74% |
| Total Puts | 127,000▲ 15.98% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 37.06%▲ 1.02% |
|---|---|
| Total Invested | $47.57M▼ 1.52% |
| Investors Holding | 66▲ 11.00% |
ESG Score
No data
About Spero Therapeutics Inc
89 employees
CEO: Ankit Mahadevia Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.